Last reviewed · How we verify
CM336 Injection
CM336 is a monoclonal antibody that targets and inhibits a specific immune checkpoint or inflammatory pathway to enhance anti-tumor immunity or reduce pathological inflammation.
At a glance
| Generic name | CM336 Injection |
|---|---|
| Sponsor | Shandong First Medical University |
| Modality | Biologic |
| Phase | Phase 3 |
Mechanism of action
CM336 is an investigational monoclonal antibody in Phase 3 development from Shandong First Medical University. While the precise molecular target has not been widely disclosed in public literature, it is designed to modulate immune responses, likely through checkpoint inhibition or cytokine pathway targeting. The drug is being evaluated for oncologic and/or immunologic indications.
Approved indications
Common side effects
Key clinical trials
- MRD-Guided BCMA/CD3 Bispecific Antibody Treatment After Stem Cell Transplant for Newly Diagnosed Multiple Myeloma (PHASE2)
- A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia (PHASE1, PHASE2)
- Study Evaluating the Efficacy and Safety of CM336 Injection in the Treatment of Light-Chain Amyloidosis (PHASE2)
- Study of CM336 in Relapsed or Refractory Multiple Myeloma Patients (PHASE3)
- A Study to Evaluate CM336 in Adults with Autoimmune Bullous Disease (PHASE1, PHASE2)
- An Open, Exploratory Clinical Study of CM336 in the Treatment of Immune Thrombocytopenia (PHASE2)
- A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CM336 Injection CI brief — competitive landscape report
- CM336 Injection updates RSS · CI watch RSS
- Shandong First Medical University portfolio CI